Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
16 Mayo 2023 - 6:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing targeted
radiotherapeutics with advanced platform technologies for central
nervous system cancers, today announced that it has received
notification from The Nasdaq Stock Market LLC that the staff has
determined that for the last 10 consecutive business days, from May
1, 2023 to May 12, 2023, the closing bid price of the Company’s
common stock has been at $1.00 per share or greater. Therefore, the
Company has regained compliance with Listing Rule 5550(a)(2).
Accordingly, Nasdaq has advised that the matter is now closed.
About Plus TherapeuticsPlus
Therapeutics, Inc. is a clinical-stage pharmaceutical company
developing targeted radiotherapeutics for difficult-to-treat
cancers of the central nervous system with the potential to enhance
clinical outcomes for patients. Combining image-guided local beta
radiation and targeted drug delivery approaches, the Company is
advancing a pipeline of product candidates with lead programs in
recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
The Company has built a robust supply chain through strategic
partnerships that enable the development, manufacturing and future
potential commercialization of its products. Plus Therapeutics is
led by an experienced and dedicated leadership team and has
operations in key cancer clinical development hubs including Austin
and San Antonio, Texas. For more information, visit
https://plustherapeutics.com/.
Investor ContactPeter VozzoICR Westwicke(443)
213-0505Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerICR Westwicke(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Plus Therapeutics (NASDAQ:PSTV)
Gráfica de Acción Histórica
De May 2023 a May 2024